Core Viewpoint - The report from Citi indicates an accelerated trend of original research drugs moving from "in-hospital" to "out-of-hospital" markets, leading to an upward revision of Alibaba Health's (00241) adjusted net profit forecasts for fiscal years 2026 and 2027 by 8% and 12% respectively, reflecting a more optimistic outlook on drug sales [1] Group 1: Financial Projections - Alibaba Health has raised its revenue growth guidance for fiscal year 2026 to 10% to 20%, up from the previous range of 5% to 10% [1] - The adjusted net profit growth guidance has also been increased to 20% to 30%, compared to the earlier forecast of 10% to 20% [1] - The strong sales performance of original and innovative drugs, particularly GLP-1 medications, has contributed to these positive adjustments [1] Group 2: Market Trends - The robust sales data from Alibaba Health and JD Health (06618) confirms the accelerating and sustainable trend of prescription drug outflow [1] - As original and innovative pharmaceutical companies expand new sales channels, online platforms like Alibaba Health and JD Health emerge as the biggest beneficiaries [1] Group 3: Target Price Adjustment - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, while maintaining an "outperform" rating [1]

Core Viewpoint - Alibaba Health (00241) shares rose over 5%, currently up 5.14% at HKD 6.14, with a trading volume of HKD 14.52 billion, following a report from Citi that raised revenue and profit growth guidance for FY2026 due to better-than-expected sales of innovative drugs, particularly GLP-1 drugs [1] Revenue Growth Guidance - Alibaba Health has increased its revenue growth guidance for FY2026 to 10% to 20%, up from the previous 5% to 10% [1] - The adjusted net profit growth guidance has also been raised to 20% to 30%, from the earlier 10% to 20% [1] Sales Performance - Strong sales data from Alibaba Health and JD Health confirm the accelerating trend of prescription drug outflow, which is deemed sustainable [1] - The shift of original and innovative drugs from "in-hospital" to "out-of-hospital" markets benefits online platforms like Alibaba Health and JD Health [1] Profit Forecast Adjustments - Citi has adjusted its net profit forecasts for Alibaba Health for FY2026 and FY2027 upwards by 8% and 12% respectively, reflecting a more optimistic outlook on drug sales [1] - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Viewpoint - The report from Citi highlights that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10%-20% and adjusted net profit growth guidance to 20%-30%, primarily driven by better-than-expected sales performance of innovative drugs, particularly GLP-1 medications [1] Company Summary - Alibaba Health's strong sales data, along with that of JD Health, confirms the acceleration and sustainability of the trend of prescription drug outflow [1] - The online platforms are identified as the biggest beneficiaries for innovative pharmaceutical companies in expanding new sales channels [1] - Citi has revised its adjusted net profit forecasts for Alibaba Health for fiscal years 2026 and 2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health has been increased from HKD 4.8 to HKD 6.5, while maintaining an "Outperform" rating [1]

Core Viewpoint - Credit Suisse reports that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10% to 20% (previously 5% to 10%) and adjusted net profit growth guidance to 20% to 30% (previously 10% to 20%), primarily due to better-than-expected sales performance of original and innovative drugs, particularly GLP-1 drugs [1] Group 1 - Alibaba Health and JD Health's strong sales data confirm the accelerating and sustainable trend of prescription drug outflow [1] - The acceleration of original drug sales from hospitals to external markets has led to an 8% and 12% upward adjustment in Alibaba Health's adjusted net profit forecasts for fiscal years 2026 and 2027, respectively [1] - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]